ADPT insider buying and SEC filings, explained
Adaptive Biotechnologies Corp · CIK 1478320
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$19.3M
Planned sales (10b5-1)
$95.2M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 27–29, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 35,643 shares between Oct 27 and Oct 29 at about $28.00 ($998K), marked as a 10b5-1 plan trade. Holdings down 9% to 377,802 shares. | SEC filing Filed Oct 29, 2026, 7:52 PM ET |
| Oct 22–26, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 35,643 shares between Oct 22 and Oct 26 at about $25.18 ($897K), marked as a 10b5-1 plan trade. Holdings down 9% to 377,802 shares. | SEC filing Filed Oct 26, 2026, 6:52 PM ET |
| Oct 19–21, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 35,643 shares between Oct 19 and Oct 21 at about $24.66 ($879K), marked as a 10b5-1 plan trade. Holdings down 9% to 377,802 shares. | SEC filing Filed Oct 21, 2026, 6:36 PM ET |
| Oct 14–16, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 35,643 shares between Oct 14 and Oct 16 at about $25.18 ($897K), marked as a 10b5-1 plan trade. Holdings down 9% to 377,802 shares. | SEC filing Filed Oct 16, 2026, 7:21 PM ET |
| Oct 9–13, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 35,643 shares between Oct 9 and Oct 13 at about $25.81 ($920K), marked as a 10b5-1 plan trade. Holdings down 9% to 377,802 shares. | SEC filing Filed Oct 13, 2026, 7:05 PM ET |
| Oct 6–8, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 35,643 shares between Oct 6 and Oct 8 at about $26.60 ($948K), marked as a 10b5-1 plan trade. Holdings down 9% to 377,802 shares. | SEC filing Filed Oct 8, 2026, 6:54 PM ET |
| Oct 6, 2026 | Planned (10b5-1) | Susan Bobulsky (Chief Commercial Officer, MRD) sold 6,444 shares at $30.00 ($193K), marked as a 10b5-1 plan trade. Holdings down 2% to 389,350 shares. | SEC filing Filed Oct 8, 2026, 6:52 PM ET |
| Oct 1–5, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 35,643 shares between Oct 1 and Oct 5 at about $28.46 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 9% to 377,802 shares. | SEC filing Filed Oct 5, 2026, 8:15 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 26,792 shares at about $28.28 ($758K), marked as a 10b5-1 plan trade. Holdings down 11% to 220,867 shares. | SEC filing Filed Oct 5, 2026, 8:12 PM ET |
| Sep 16, 2026 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 115,406 shares at about $28.06 ($3.2M), marked as a 10b5-1 plan trade. Holdings down 34% to 220,867 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Susan Bobulsky (Chief Commercial Officer, MRD) sold 1,195 shares at $27.00 ($32K), marked as a 10b5-1 plan trade. Holdings down <1% to 395,794 shares. | SEC filing Filed Sep 17, 2026 |
| Aug 26, 2026 | Sale | Katey Einterz Owen (Director) sold 9,615 shares at $26.00 ($250K). Holdings down 11% to 78,639 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 28, 2026 |
| Aug 18, 2026 | Sale | Robert Hershberg (Director) sold 30,664 shares at about $24.40 ($748K). Holdings down 40% to 46,683 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 20, 2026 |
| Aug 17, 2026 | Sale | Peter M. Neupert (Director) sold 124,690 shares at about $25.15 ($3.1M). Holdings down 49% to 130,625 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 19, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Susan Bobulsky (Chief Commercial Officer, MRD) sold 3,000 shares at $25.00 ($75K), marked as a 10b5-1 plan trade. Holdings down 1% to 396,989 shares. | SEC filing Filed Aug 12, 2026 |
| Jul 30, 2026 | Planned (10b5-1) | Susan Bobulsky (Chief Commercial Officer, MRD) sold 1,299 shares at $24.00 ($31K), marked as a 10b5-1 plan trade. Holdings down <1% to 399,989 shares. | SEC filing Filed Aug 3, 2026 |
| Jul 21, 2026 | Planned (10b5-1) | Harlan S. Robins (Chief Scientific Officer) sold 492,400 shares at about $21.89 ($10.8M), marked as a 10b5-1 plan trade. Holdings down 38% to 812,058 shares. | SEC filing Filed Jul 23, 2026 |
| Jul 16, 2026 | Planned (10b5-1) | Susan Bobulsky (Chief Commercial Officer, MRD) sold 5,000 shares at $23.00 ($115K), marked as a 10b5-1 plan trade. Holdings down 1% to 401,288 shares. | SEC filing Filed Jul 20, 2026 |
| Jul 15, 2026 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 105,762 shares at about $22.59 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 31% to 230,713 shares. | SEC filing Filed Jul 17, 2026 |
| Jul 2, 2026 | Planned (10b5-1) | Harlan S. Robins (Chief Scientific Officer) sold 386,240 shares at about $22.01 ($8.5M), marked as a 10b5-1 plan trade. Holdings down 27% to 1,019,658 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Susan Bobulsky (Chief Commercial Officer, MRD) sold 487 shares at $22.00 ($11K), marked as a 10b5-1 plan trade. Holdings down <1% to 406,288 shares. | SEC filing Filed Jul 6, 2026 |
| Jul 1–2, 2026 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 95,842 shares between Jul 1 and Jul 2 at about $22.51 ($2.2M), marked as a 10b5-1 plan trade. Holdings down 29% to 230,713 shares. | SEC filing Filed Jul 6, 2026 |
| Jun 26–29, 2026 | Planned (10b5-1) | Sharon Benzeno (Chief Commercial Ofc Imm Med) sold 165,802 shares between Jun 26 and Jun 29 at about $21.13 ($3.5M), marked as a 10b5-1 plan trade. Holdings down 43% to 221,278 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Susan Bobulsky (Chief Commercial Officer, MRD) sold 5,000 shares at $20.50 ($103K), marked as a 10b5-1 plan trade. Holdings down 1% to 406,775 shares. | SEC filing Filed Jun 29, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Michelle Renee Griffin (Director) sold 52,084 shares at about $20.18 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 77% to 15,625 shares. | SEC filing Filed Jun 29, 2026 |
| Jun 15–16, 2026 | Planned (10b5-1) | Harlan S. Robins (Chief Scientific Officer) sold 106,160 shares between Jun 15 and Jun 16 at about $17.41 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 7% to 1,405,898 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 11, 2026 | Planned (10b5-1) | Susan Bobulsky (Chief Commercial Officer, MRD) sold 5,000 shares at $19.00 ($95K), marked as a 10b5-1 plan trade. Holdings down 1% to 411,775 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Susan Bobulsky (Chief Commercial Officer, MRD) sold 11,000 shares at $18.00 ($198K), marked as a 10b5-1 plan trade. Holdings down 3% to 416,775 shares. | SEC filing Filed Jun 8, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 39,741 shares at $17.49 ($695K), marked as a 10b5-1 plan trade. Holdings down 14% to 250,934 shares. | SEC filing Filed Jun 8, 2026 |
| May 18, 2026 | Sale | Kyle Piskel (CFO) sold 3,115 shares at $13.04 ($41K). Holdings down 1% to 256,725 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
| Apr 27, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 19,037 shares at about $14.23 ($271K), marked as a 10b5-1 plan trade. Holdings down 5% to 377,802 shares. | SEC filing Filed Apr 29, 2026 |
| Apr 22–24, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 57,180 shares between Apr 22 and Apr 24 at about $13.96 ($798K), marked as a 10b5-1 plan trade. Holdings down 13% to 382,132 shares. | SEC filing Filed Apr 24, 2026 |
| Apr 17–21, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 69,061 shares between Apr 17 and Apr 21 at about $14.60 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 15% to 395,146 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 14–16, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 57,180 shares between Apr 14 and Apr 16 at about $14.45 ($826K), marked as a 10b5-1 plan trade. Holdings down 12% to 408,160 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 9–13, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 57,180 shares between Apr 9 and Apr 13 at about $13.26 ($758K), marked as a 10b5-1 plan trade. Holdings down 12% to 421,174 shares. | SEC filing Filed Apr 13, 2026 |
| Apr 8, 2026 | Planned (10b5-1) | Harlan S. Robins (Chief Scientific Officer) sold 10,000 shares at about $14.85 ($149K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,512,058 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 8, 2026 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 22,564 shares at about $15.07 ($340K), marked as a 10b5-1 plan trade. Holdings down 8% to 271,154 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 6–8, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 69,061 shares between Apr 6 and Apr 8 at about $14.34 ($991K), marked as a 10b5-1 plan trade. Holdings down 14% to 434,188 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 6–8, 2026 | Planned (10b5-1) | Chad M. Robins (CEO and Director) sold 120,595 shares between Apr 6 and Apr 8 at about $14.65 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 5% to 2,180,518 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 1–2, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 38,120 shares between Apr 1 and Apr 2 at about $14.53 ($554K), marked as a 10b5-1 plan trade. Holdings down 8% to 447,202 shares. | SEC filing Filed Apr 2, 2026 |
| Mar 27–31, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 57,180 shares between Mar 27 and Mar 31 at about $13.14 ($751K), marked as a 10b5-1 plan trade. Holdings down 11% to 455,878 shares. | SEC filing Filed Mar 31, 2026 |
| Mar 24–26, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 57,180 shares between Mar 24 and Mar 26 at about $14.03 ($802K), marked as a 10b5-1 plan trade. Holdings down 11% to 468,892 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 19–23, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 57,180 shares between Mar 19 and Mar 23 at about $13.46 ($770K), marked as a 10b5-1 plan trade. Holdings down 11% to 481,906 shares. | SEC filing Filed Mar 23, 2026 |
| Mar 16–18, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 57,180 shares between Mar 16 and Mar 18 at about $13.33 ($762K), marked as a 10b5-1 plan trade. Holdings down 10% to 494,920 shares. | SEC filing Filed Mar 18, 2026 |
| Mar 11, 2026 | Sale | Susan Bobulsky (Chief Commercial Officer, MRD) sold 41,338 shares at $13.17 ($544K). Holdings down 9% to 427,775 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Mar 11, 2026 | Sale | Sharon Benzeno (Chief Commercial Ofc Imm Med) sold 63,103 shares at $13.17 ($831K). Holdings down 19% to 272,751 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Mar 11, 2026 | Sale | Harlan S. Robins (Chief Scientific Officer) sold 470,266 shares at $13.17 ($6.2M). Holdings down 24% to 1,522,058 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Mar 11–13, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 179,703 shares between Mar 11 and Mar 13 at about $13.21 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 26% to 507,934 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 11, 2026 | Sale | Kyle Piskel (CFO) sold 18,672 shares at $13.17 ($246K). Holdings down 7% to 259,840 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Mar 11, 2026 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 30,593 shares at about $14.08 ($431K), marked as a 10b5-1 plan trade. Holdings down 10% to 291,374 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 11, 2026 | Sale | Chad M. Robins (CEO and Director) sold 470,167 shares at $13.17 ($6.2M). Holdings down 17% to 2,301,113 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Mar 11, 2026 | Sale | Michelle Renee Griffin (Director) sold 15,394 shares at about $13.91 ($214K). Holdings down 50% to 15,625 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Mar 6–10, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 81,342 shares between Mar 6 and Mar 10 at about $14.90 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 11% to 643,471 shares. | SEC filing Filed Mar 10, 2026 |
| Mar 5, 2026 | Sale | Francis Lo (Chief People Officer) sold 38,074 shares at $15.09 ($575K). Holdings down 11% to 321,967 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 9, 2026 |
| Mar 3–5, 2026 | Planned (10b5-1) | Julie Rubinstein (President / COO) sold 92,823 shares between Mar 3 and Mar 5 at about $16.09 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 14% to 575,235 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Michelle Renee Griffin (Director) sold 48,044 shares at about $15.30 ($735K), marked as a 10b5-1 plan trade. Holdings down 76% to 15,394 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 2–3, 2026 | Planned (10b5-1) | Harlan S. Robins (Chief Scientific Officer) sold 24,233 shares between Mar 2 and Mar 3 at about $16.19 ($392K), marked as a 10b5-1 plan trade. Holdings down 2% to 1,155,291 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 27–Mar 3, 2026 | Planned (10b5-1) | Chad M. Robins (CEO and Director) sold 524,998 shares between Feb 27 and Mar 3 at about $15.85 ($8.3M), marked as a 10b5-1 plan trade. Holdings down 21% to 1,934,247 shares. | SEC filing Filed Mar 3, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Kyle Piskel (CFO) sold 2,145 shares at $18.46 ($40K), marked as a 10b5-1 plan trade. Holdings down 1% to 216,637 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 2–3, 2026 | Planned (10b5-1) | Harlan S. Robins (Chief Scientific Officer) sold 42,788 shares between Feb 2 and Feb 3 at about $18.68 ($799K), marked as a 10b5-1 plan trade. Holdings down 4% to 1,179,524 shares. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Chad M. Robins (CEO and Director) sold 124,998 shares at about $18.44 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 5% to 2,459,245 shares. | SEC filing Filed Feb 4, 2026 |
| Jan 12, 2026 | Planned (10b5-1) | Kyle Piskel (CFO) sold 4,290 shares at $18.00 ($77K), marked as a 10b5-1 plan trade. Holdings down 2% to 216,637 shares. | SEC filing Filed Jan 14, 2026 |
| Jan 12, 2026 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 79,590 shares at $17.73 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 20% to 315,978 shares. | SEC filing Filed Jan 14, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Harlan S. Robins (Chief Scientific Officer) sold 10,000 shares at about $16.44 ($164K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,222,312 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Chad M. Robins (CEO and Director) sold 124,998 shares at about $15.59 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 5% to 2,584,243 shares. | SEC filing Filed Jan 7, 2026 |
| Dec 22, 2025 | Planned (10b5-1) Amended filing | Francis Lo (Chief People Officer) sold 4,394 shares at about $17.50 ($77K), marked as a 10b5-1 plan trade. Holdings down 1% to 315,978 shares. This amends a filing from Dec 29, 2025. | SEC filing Filed Jan 7, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 3,125 shares at about $16.08 ($50K), marked as a 10b5-1 plan trade. Holdings down 1% to 315,978 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 15, 2025 | Planned (10b5-1) | Francis Lo (Chief People Officer) sold 113,890 shares at about $15.57 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 26% to 315,978 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 10, 2025 | Sale | Robert Hershberg (Director) sold 22,968 shares at $16.00 ($367K). Holdings down 33% to 46,722 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 12, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | Sharon Benzeno (Chief Commercial Ofc Imm Med) sold 12,604 shares at about $16.85 ($212K), marked as a 10b5-1 plan trade. Holdings down 4% to 296,791 shares. | SEC filing Filed Dec 8, 2025 |
| Dec 3–4, 2025 | Planned (10b5-1) | Harlan S. Robins (Chief Scientific Officer) sold 37,212 shares between Dec 3, 2025 and Dec 4, 2025 at about $18.07 ($673K), marked as a 10b5-1 plan trade. Holdings down 3% to 1,232,312 shares. | SEC filing Filed Dec 5, 2025 |
| Nov 28, 2025 | Planned (10b5-1) | Kyle Piskel (CFO) sold 162,820 shares at about $19.50 ($3.2M), marked as a 10b5-1 plan trade. Holdings down 43% to 216,637 shares. | SEC filing Filed Dec 2, 2025 |
| Nov 26–Dec 1, 2025 | Planned (10b5-1) | Chad M. Robins (CEO and Director) sold 160,734 shares between Nov 26, 2025 and Dec 1, 2025 at about $19.10 ($3.1M), marked as a 10b5-1 plan trade. Holdings down 6% to 2,709,241 shares. | SEC filing Filed Dec 1, 2025 |
| Nov 20–21, 2025 | Planned (10b5-1) | Sharon Benzeno (Chief Commercial Ofc Imm Med) sold 606,402 shares between Nov 20, 2025 and Nov 21, 2025 at about $16.73 ($10.1M), marked as a 10b5-1 plan trade. Holdings down 67% to 296,791 shares. | SEC filing Filed Nov 24, 2025 |
| Nov 17, 2025 | Sale | Kyle Piskel (CFO) sold 238 shares at $14.05 ($3K). Holdings down <1% to 269,343 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 18, 2025 |
| Nov 10, 2025 | Planned (10b5-1) | Harlan S. Robins (Chief Scientific Officer) sold 10,000 shares at about $14.82 ($148K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,269,524 shares. | SEC filing Filed Nov 12, 2025 |
| Nov 10–12, 2025 | Planned (10b5-1) | Chad M. Robins (CEO and Director) sold 89,265 shares between Nov 10, 2025 and Nov 12, 2025 at about $14.73 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 3% to 2,869,975 shares. | SEC filing Filed Nov 12, 2025 |
56 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ADPT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.